Indivior PLC (LON:INDV) had its price objective boosted by investment analysts at Jefferies Group from GBX 320 ($4.26) to GBX 330 ($4.40) in a research note issued on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s price target indicates a potential downside of 0.66% from the stock’s current price.
Several other brokerages have also recently commented on INDV. Stifel Nicolaus raised their price target on shares of Indivior PLC from GBX 310 ($4.13) to GBX 350 ($4.66) and gave the company a “buy” rating in a research report on Monday, July 11th. Numis Securities Ltd assumed coverage on shares of Indivior PLC in a research report on Friday, July 22nd. They issued a “buy” rating and a GBX 340 ($4.53) price target for the company. Citigroup Inc. cut shares of Indivior PLC to a “neutral” rating and raised their price target for the company from GBX 230 ($3.06) to GBX 280 ($3.73) in a research report on Tuesday, July 19th. Deutsche Bank AG raised their price target on shares of Indivior PLC from GBX 280 ($3.73) to GBX 290 ($3.86) and gave the company a “buy” rating in a research report on Friday, July 8th. Finally, Morgan Stanley raised shares of Indivior PLC to an “overweight” rating and lifted their price objective for the stock from GBX 190 ($2.53) to GBX 280 ($3.73) in a research report on Tuesday, June 14th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Indivior PLC has an average rating of “Buy” and an average price target of GBX 346.43 ($4.61).
Shares of Indivior PLC (LON:INDV) opened at 332.20 on Monday. The firm has a 50-day moving average of GBX 311.05 and a 200 day moving average of GBX 223.58. The stock’s market capitalization is GBX 2.39 billion. Indivior PLC has a 12-month low of GBX 126.60 and a 12-month high of GBX 365.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/18/jefferies-group-boosts-indivior-plc-indv-price-target-to-gbx-330.html
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.
Receive News & Ratings for Indivior PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Indivior PLC and related companies with MarketBeat.com’s FREE daily email newsletter.